Company insight
An innovative solution for menstrual health
A breakthrough study by Gencor highlights Levagen+ as a fast-acting supplement for menstrual discomfort.
with prenatal health, menopause and mental health dominating the conversation. The women’s sexual and reproductive health supplement market is growing faster than men’s – and it’s showing no signs of slowing down. According to NBJ, the market size is approaching $2bn (including prenatal and menopause supplements), so this is a category one can’t afford to ignore. Brands will do even better by targeting women in different age groups with supplements specifically designed to support common areas of concern that have not been monopolised in the marketplace, like menstrual health.
W
According to global health statistics, nearly one billion women worldwide report experiencing significant physical pain daily, with roughly one in four women, which translates into almost 700 million, facing health issues that hinder their everyday activities. Some health issues still remain taboo and according to available data, around 80% of women experience menstrual cramps at some point in their lives, with over half (51%) reporting experiencing pain during every period, with many experiencing severe pain that disrupts their daily life.
So, let’s talk about it
Menstrual pain or primary dysmenorrhea (menstrual pain without any underlying pathology) is the leading gynecological condition in women of reproductive age. It is estimated to be the prime cause of chronic pelvic pain worldwide according to the World Health Organisation. Its prevalence rate varies 45–95% and is associated with restricting daily activity, work and school absenteeism, and personal distress. While the primary mechanisms of dysmenorrhea are yet to be fully established,
20
omen’s health is finally and rightfully taking centre stage in the health and wellness space
A new solution
A recent human clinical study investigated the palmitoylethanolamide (PEA) ingredient Levagen+ as a safe, innovative and effective supplement to ease acute menstrual discomfort. Preclinical research suggests that PEA’s primary mechanism of action is to provide relief from occasional discomfort and support a balanced inflammatory response, which may be through the activation of peroxisome proliferator-activated receptor-a (PPAR). Therefore, this study aimed to assess the effectiveness of PEA in alleviating acute menstrual pain in otherwise healthy women.
Menstrual pain is often perceived as a ‘normal’ facet of a woman’s menstrual cycle.
the main cause of painful symptoms is identified to be the hyper-production of uterine prostaglandins, namely prostaglandin F2- (PGF2) and prostaglandin E2 (PGE2), which are most significant during the initial days of menstruation.
Prostaglandins are natural chemicals produced in the lining of the uterus. Higher levels of prostaglandins are associated with more severe menstrual cramps. Apart from its regulatory effects on inflammation, pain and body temperature, prostaglandin production is also reported to be responsible for secondary symptoms of menstrual pain, such as diarrhoea, nausea, vomiting and headaches. Additionally, women encountering dysmenorrhea may have increased expression of pro- inflammatory mediators and a higher body temperature.
Period pain can feel like a throbbing, cramping pain in the lower abdomen. It can also be felt in the back or legs. Most people experience mild pain and discomfort during their period. But for some, the pain and cramping are so severe that it impacts their ability to function normally. Limited research suggests that period pain can be as painful as a heart attack.
The randomised, crossover, double-blind, placebo-controlled trial included 80 menstruating females aged 18 years and older self-reporting mild to moderate menstruating cramp pain. Each randomised bottle of the trial product contained either 350mg of Levagen+ or the placebo (350mg of microcrystalline cellulose). Pain scores were recorded on the numerical pain rating scale (NRS) every 30 minutes for up to four hours. The findings indicate Levagen+ significantly reduced pain scores compared with placebo at 1, 1.5, 2, and 2.5 hours post-dose, with a pain reduction of approximately 25% by 2.5 hours compared with the placebo group. This study demonstrates that Levagen+ was an effective strategy to reduce acute menstrual pain in healthy women.
The results of this study show that Levagen+ can be an effective and quick- acting supplement to support women during their monthly cycles. Gencor will continue to invest in clinical research to explore how Levagen+ can further support female health. ●
References available upon request.
www.gencorpacific.com Ingredients Insight /
www.ingredients-insight.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94
